Valuation: CSL Limited

Market Cap 40.89B 35.74B 33.05B 30.33B 57.41B 3,940B 58.4B 394B 155B 1,924B 154B 150B 6,643B P/E 2026 *
-46x
P/E 2027 * 28.5x
Enterprise Value 49.74B 43.48B 40.21B 36.9B 69.83B 4,793B 71.04B 480B 188B 2,341B 187B 183B 8,080B EV / Sales 2026 *
3.23x
EV / Sales 2027 * 3.13x
Free-Float
99.3%
Yield 2026 *
3.34%
Yield 2027 * 3.43%
1 day+1.96%
1 week-0.95%
Current month+8.37%
1 month+17.03%
3 months-9.60%
6 months-29.16%
Current year-27.98%
1 week 120.1
Extreme 120.1
125.53
1 month 105.42
Extreme 105.415
126.98
Current year 90
Extreme 90
184.62
1 year 90
Extreme 90
275.79
3 years 90
Extreme 90
313.55
5 years 90
Extreme 90
319.78
10 years 90
Extreme 90
342.75
Manager TitleAgeSince
Chief Executive Officer 63 2026-02-10
Director of Finance/CFO 52 2025-10-06
Chief Operating Officer - 2025-04-30
Director TitleAgeSince
Director/Board Member 72 2018-10-16
Director/Board Member 70 2011-02-01
Director/Board Member 71 2019-12-08
Date Insider Type Main position Quantity % Market Cap.
6/1/26 Buy

Director

1,036 0.0002%
5/26/26 Buy

Chief Executive Officer

1,100 0.0002%
5/26/26 Buy

Chief Executive Officer

1,100 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
+1.79%-0.95%-49.75%-51.96% 40.81B
+2.18%+1.65%+23.91%-5.51% 67.6B
+0.85%-4.92%+40.11%+199.67% 51.32B
+0.94%+39.60%+39.60%+39.60% 42.97B
+5.92%+5.03%+62.63%-25.10% 29.12B
-7.51%-17.52%+96.97%-47.96% 27.09B
+1.36%-1.58%+68.50%+88.88% 22.99B
-2.94%+9.28%+9.66%+190.29% 21.55B
+2.15%-1.61%+58.33%+129.01% 16.38B
-2.86%-10.95%+70.49%+340.72% 16.2B
Average +0.20%-0.55%+42.05%+85.76% 33.6B
Weighted average by Cap. +0.71%-0.92%+34.75%+63.10%

Financials

2026 *2027 *
Net sales 15.39B 13.45B 12.44B 11.42B 21.61B 1,483B 21.98B 148B 58.29B 724B 57.8B 56.53B 2,500B 15.64B 13.67B 12.64B 11.6B 21.95B 1,507B 22.33B 151B 59.21B 736B 58.72B 57.43B 2,540B
Net income -894M -781M -722M -663M -1.25B -86.1B -1.28B -8.61B -3.38B -42.05B -3.36B -3.28B -145B 1.18B 1.03B 956M 878M 1.66B 114B 1.69B 11.41B 4.48B 55.68B 4.44B 4.35B 192B
Net Debt 8.85B 7.74B 7.15B 6.56B 12.42B 853B 12.64B 85.31B 33.51B 416B 33.23B 32.5B 1,438B 8.07B 7.05B 6.52B 5.99B 11.33B 778B 11.53B 77.8B 30.56B 380B 30.31B 29.64B 1,311B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,904
Date Price Change Volume
26-07-16 A$124.54 +2.12% 1,020,624
26-07-16 A$121.95 +0.16% 1,047,549
26-07-15 A$121.75 -0.98% 907,829
26-07-14 A$122.96 +1.34% 697,252
26-07-13 A$121.34 -1.26% 1,504,392
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
85.38USD
Average target price
96.64USD
Spread / Average Target
+13.18%

Quarterly revenue - Rate of surprise